Matches in SemOpenAlex for { <https://semopenalex.org/work/W2316731438> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2316731438 endingPage "193" @default.
- W2316731438 startingPage "193.3" @default.
- W2316731438 abstract "<h3>Background</h3> Rituximab (RTX) is monoclonal antibody that selectively targets CD20+ B cells. The combination of RTX with MTX significantly improves disease symptoms in rheumathodi arthritis (RA) patients who have had an inadequate response to conventional DMARD therapy, and has been shown to improve quality of life in those patients. This is the only study that assessed efficacy and safety of RTX in daily practice in Serbia <h3>Objectives</h3> To determine the safety and efficacy of additional courses of RTX in patients with RA. <h3>Methods</h3> This is interim analysis of prospective noninterventional trial that enrolled 130 RA patients with inadequate response to previous biologic and/or synthetic DMARDs treated with RTX (age 50.37±11.59 years; 85.3% females and 14.7% males; disease duration 8.4±6.5 years). Patients were eligible for additional RTX courses (2 infusions of 1,000 mg given 2 weeks apart) if they exhibited disease reactivation measeured by DAS28. Efficacy was assessed by DAS28 (number of tender and swollen joints, VAS-GH, sedimentation) and the disability index of the Health Assessment Questionnaire at baseline and 24 weeks after first, second and third course. Safety was assessed by the number and severity of registered adverse events (AE). <h3>Results</h3> 114 patients received >1 course of RTX (58 received 2 courses and 10 received 3 courses). Mean DAS28 scores decreased significantly from 6.41±0.97 at baseline to 4.91±1.65/4.33±1.23 and 3.86±1.43, 24 weeks after first/second/third RTX courses; p<0.001. The proportions of patients with low disease activity (DAS28<3.2) and in remission (DAS28<2.6), increased following third RTX course (4.3% and 17.4%) compared to baseline. Proportion of patients with moderate disease activity (DAS28, 3.2-5.1) increased after 3 RTX course from 7.8% to 60.9%. Total HAD-DI score, before and after third RTX course was 2,25 (1,19) and 1,37 (1,78), respectively; p<0,004. During the first/second/third courses AE were reported in 8/2/1 patients. No SAEs were reported. <h3>Conclusions</h3> During 3 courses of treatment, rituximab showed significant decrease of DAS28 and and increased quality of life measured by HAQ-DI questionnaire after each following rituximab course. <h3>Disclosure of Interest</h3> None Declared" @default.
- W2316731438 created "2016-06-24" @default.
- W2316731438 creator A5000720792 @default.
- W2316731438 creator A5039622549 @default.
- W2316731438 creator A5042601081 @default.
- W2316731438 creator A5066297740 @default.
- W2316731438 creator A5081184110 @default.
- W2316731438 date "2013-06-01" @default.
- W2316731438 modified "2023-09-23" @default.
- W2316731438 title "THU0116 Safety and efficacy of courses of rituximab in patients with rheumatoid arthritis - ritam study" @default.
- W2316731438 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2081" @default.
- W2316731438 hasPublicationYear "2013" @default.
- W2316731438 type Work @default.
- W2316731438 sameAs 2316731438 @default.
- W2316731438 citedByCount "0" @default.
- W2316731438 crossrefType "journal-article" @default.
- W2316731438 hasAuthorship W2316731438A5000720792 @default.
- W2316731438 hasAuthorship W2316731438A5039622549 @default.
- W2316731438 hasAuthorship W2316731438A5042601081 @default.
- W2316731438 hasAuthorship W2316731438A5066297740 @default.
- W2316731438 hasAuthorship W2316731438A5081184110 @default.
- W2316731438 hasConcept C126322002 @default.
- W2316731438 hasConcept C141071460 @default.
- W2316731438 hasConcept C159110408 @default.
- W2316731438 hasConcept C1862650 @default.
- W2316731438 hasConcept C197934379 @default.
- W2316731438 hasConcept C198451711 @default.
- W2316731438 hasConcept C2777575956 @default.
- W2316731438 hasConcept C2778143017 @default.
- W2316731438 hasConcept C2779338263 @default.
- W2316731438 hasConcept C2779951463 @default.
- W2316731438 hasConcept C2780653079 @default.
- W2316731438 hasConcept C535046627 @default.
- W2316731438 hasConcept C61943457 @default.
- W2316731438 hasConcept C71924100 @default.
- W2316731438 hasConceptScore W2316731438C126322002 @default.
- W2316731438 hasConceptScore W2316731438C141071460 @default.
- W2316731438 hasConceptScore W2316731438C159110408 @default.
- W2316731438 hasConceptScore W2316731438C1862650 @default.
- W2316731438 hasConceptScore W2316731438C197934379 @default.
- W2316731438 hasConceptScore W2316731438C198451711 @default.
- W2316731438 hasConceptScore W2316731438C2777575956 @default.
- W2316731438 hasConceptScore W2316731438C2778143017 @default.
- W2316731438 hasConceptScore W2316731438C2779338263 @default.
- W2316731438 hasConceptScore W2316731438C2779951463 @default.
- W2316731438 hasConceptScore W2316731438C2780653079 @default.
- W2316731438 hasConceptScore W2316731438C535046627 @default.
- W2316731438 hasConceptScore W2316731438C61943457 @default.
- W2316731438 hasConceptScore W2316731438C71924100 @default.
- W2316731438 hasIssue "Suppl 3" @default.
- W2316731438 hasLocation W23167314381 @default.
- W2316731438 hasOpenAccess W2316731438 @default.
- W2316731438 hasPrimaryLocation W23167314381 @default.
- W2316731438 hasRelatedWork W2054241726 @default.
- W2316731438 hasRelatedWork W2065131845 @default.
- W2316731438 hasRelatedWork W2091629131 @default.
- W2316731438 hasRelatedWork W2105226906 @default.
- W2316731438 hasRelatedWork W2119875305 @default.
- W2316731438 hasRelatedWork W2320240246 @default.
- W2316731438 hasRelatedWork W2801221612 @default.
- W2316731438 hasRelatedWork W2954284607 @default.
- W2316731438 hasRelatedWork W3178040701 @default.
- W2316731438 hasRelatedWork W562161591 @default.
- W2316731438 hasVolume "71" @default.
- W2316731438 isParatext "false" @default.
- W2316731438 isRetracted "false" @default.
- W2316731438 magId "2316731438" @default.
- W2316731438 workType "article" @default.